CJC-1295 NO DAC + Ipamorelin (5 mg + 5 mg)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously, typically before bed or upon waking. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 3.33 mg/mL total, 1 unit = 0.01 mL » 33.3 mcg of each peptide on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C; use within ~28 days; avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (CJC-1295 NO DAC + Ipa, 10 mg blend each):

• 8 weeks: ~3 vials. 12 weeks: ~4 vials. 16 weeks: ~5 vials.

Insulin Syringes (U-100, 30- or 50-unit preferred for low volumes):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (4 vials): 2 bottles. 16 weeks (5 vials): 2 bottles.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• For doses under 10 units, use 30- or 50-unit syringes for better precision.

How This Works

CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29 amino acid peptide) that stimulates pulsatile GH release from the pituitary. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5 to 2.5 hours that elicits a rapid GH pulse peaking around 40 minutes post-dose. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports sustained GH and IGF-1 elevation through pulsatile release patterns.
• Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation.
• Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models.
• Generally well tolerated; possible transient effects may include flushing, headache, or injection-site

reactions.

• Some individuals report increased appetite, water retention, or tingling sensations.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy needs.
• Combine resistance training and aerobic activity to reinforce metabolic adaptations.
• Prioritize sleep quality, as GH is predominantly released during deep sleep.
• Manage stress to support optimal hormonal balance and recovery.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults (PubMed).
2. Once-daily CJC-1295 normalizes growth in GHRH knockout mouse (PubMed).
3. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue (PubMed).
4. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (PubMed).